Aspen says profit rose notably in its year to end-June
Earnings per share could rise as much as 37%, with the company also getting a lift from asset sales
17 August 2022 - 09:33
SA’s biggest pharmaceutical maker, Aspen Pharmacare, has flagged a profit rise of at least a fifth for its year to end-June, also reporting it has seen an expected improvement in a manufacturing business hit by supply-chain disruptions.
Normalised headline earnings per share (HEPS) from continuing operations are expected to rise between 20% and 25% to as much as 1,637.2c to end-June, the group said in a short trading update, while earnings per share could rise as much as 37%...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.